Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | PANK3 | Q9H999 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1812898 | 0.77 | NNMT (0.47) | ALDH1A1LMNAKMT2ASMN1; SMN2POLB | |
| SCHEMBL17653940 | 0.77 | ALDH1A1 (0.50) | ALDH1A1LMNAKMT2APOLBHTT | |
| SCHEMBL31292392 | 0.75 | ALDH1A1 (0.46) | ALDH1A1LMNAKMT2ASMN1; SMN2POLB | |
| SCHEMBL28563266 | 0.75 | ALDH1A1 (0.47) | ALDH1A1LMNAKMT2APANK3POLB | |
| Lithium Ion SCHEMBL22265863 | 0.74 | ALDH1A1 (0.43) | ALDH1A1LMNAKMT2ACSF1RPANK3 | |
| SCHEMBL22278214 | 0.73 | ALDH1A1 (0.42) | ALDH1A1LMNAKMT2ACSF1RPANK3 | |
| SCHEMBL6666780 | 0.72 | MAPT (0.45) | ALDH1A1LMNAKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL29446795 | 0.72 | MAPT (0.45) | ALDH1A1LMNAKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL5798744 | 0.70 | ALDH1A1 (0.51) | ALDH1A1LMNAKMT2ASMN1; SMN2POLB | |
| SCHEMBL8303468 | 0.70 | NPC1 (0.55) | ALDH1A1LMNAKMT2APOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1801108-B9 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-1801108-B1 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | ALDH1A1 2661/4885LMNA 2526/4885KMT2A 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.